

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
WILSON et al

Serial No. 10/766,942

Filed: January 30, 2004



Atty. Ref.: 3911-21

TC/A.U.: Unassigned

Examiner: Unassigned

For: BENZOAZINE MONO-N-OXIDES AND BENZOAZINE 1,4 DI-N-OXIDES
AND COMPOSITIONS THEREFROM FOR THE THERAPEUTIC USE IN
CANCER TREATMENTS

* * * * *

May 18, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449. All listed documents are attached. This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____

Leonard C. Mitchard
Reg. No. 29,009

LCM:lfm
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

3911-21

SERIAL NO.

10/766,942

APPLICANT

WILSON et al

(Use several sheets if necessary)

FILING DATE

TC/A.U.

January 30, 2004

Unassigned

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3,957,799	05/1976	Yale et al			
	3,991,189	11/1976	Seng et al			
	4,001,410	01/1977	Ley et al			
	3,868,372	02/1975	Hardtmann			
	5,484,612	01/1996	Brown			
	5,597,582	01/1997	Brown et al			
	5,827,850	10/1998	Brown et al			
	5,624,925	04/1997	Lee et al.			
	5,849,738	12/1998	Lee et al			
	5,616,584	04/1997	Lee et al			
	6,362,184	03/2002	Lee et al			
	6,153,610	11/2000	Brown et al			
	2002/0103200	08/2002	Lee et al			

FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
	WO 97/11699	04/1997	WIPO				
	NZ 228323	09/1989	NZ			ABSTR..	
	NZ 315964	01/1997	NZ			ABSTR.	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

✓	Anderson, R.F., et al; "Activation of 3-Amino-1,2,4-benzotriazine 1,4-Dioxide Antitumor Agents to Oxidizing Species Following Their One-Electron Reduction"; <i>J Am. Chem. Soc.</i> ; 2003, 125, pp. 748-756 (Web Publication date 12/19/2002).
✓	Hay, M.P., et al, "Structure-Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine"; <i>J. Med. Chem.</i> ; 2003, 46, pp. 169-182 (Published on Web 12/02/2002).
✓	Hay, M.P. et al; "New and versatile syntheses of 3-alkyl- and 3-aryl-1,2,4-benzotriazine 1,4-dioxides: preparation of the bioreductive cytotoxins SR 4895 and SR 4941"; <i>Tetrahedron Letters</i> ; 43 (2002) pp 9569-9571.
✓	Jones, G.D.D. et al; "Dual Action of Tirapazamine in the Induction of DNA Strand Breaks"; <i>Cancer Research</i> ; 56, pp1584-1590, April 1, 1996.
✓	Daniels, J. S., et al; "Direct Evidence for Bimodal DNA Damage Induced by Tirapazamine"; <i>Chem. Research Boxicol.</i> ; 11; pp. 1254-1257, 1998.
✓	Hwang, J-T., et al; "Reaction of the Hypoxia-Selective Antitumor Agent Tirapazamine with a C1'-Radical in Single-Stranded and Double-Stranded DNA: The Drug and Its Metabolites Can Serve as Surrogates for Molecular Oxygen in Radical-Mediated DNA Damage Reactions"; <i>Biochemistry</i> , 38, pp 14248-14255 (1999).
✓	Siim, B.G., et al; "Selective Potentiation of the Hypoxic Cytotoxicity of Tirapazamine by Its 1-N-Oxide Metabolite SR 4317"; <i>Cancer Research</i> ; 64, pp 736-742, January 15, 2004.
✓	New Zealand Patents Act 1953, Complete Specification; Application No. 315964; Int'l No. PCT/US96/13517; "Oral gel capsule formulation of 1,2,4-benzotriazine oxides"; Sanofi Pharmaceuticals Inc., pp 1-16.
✓	New Zealand Patents Act 1953, Complete Specification, Application No. 22832; "1,2,4-Benzotriazine Oxides as Radiosensitizers and Selective Cytotoxic Agents"; pp 1-40, Drwg. Figs. 1-3.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.